Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases

Lancet Oncology

Volumn 7, Issue 5, 2006, Pages 425-430

  Herr, Ingrid ^a,b   Pfitzenmaier, Jesco ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETAMETHASONE; CORTICOSTERONE; CORTISONE; DEXAMETHASONE; FLUOCINOLONE; GLUCOCORTICOID; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; TENIPOSIDE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; COLON CARCINOMA; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; GRAFT REJECTION; HUMAN; LYMPHOMA; NAUSEA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SKIN CANCER; SOLID TUMOR; TUMOR GROWTH; VOMITING;

EID: 33645991782     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70694-5     Document Type: Note

References (72)

1. Planey S., and Litwack G. Glucocorticoid-induced apoptosis in lymphocytes. Biochem Biophys Res Commun 279 (2000) 307-312
2. Fakih M., Johnson C., and Trump D. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 60 (2002) 553-561
3. Rutz H. Effects of corticosteroid use on treatment of solid tumours. Lancet 360 (2002) 1969-1970
4. Jemal A., Tiwari R., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
5. Huggins C., and Hodges C. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
6. Pienta K., and Smith D. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55 (2005) 300-318
7. Tannock I., Osoba D., Stockler M., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
8. Kantoff P., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17 (1999) 2506-2513
9. Petrylak D., Tangen C., Hussain M., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
10. Tannock I., de Wit R., Berry W., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
11. Hench P., Kendall E., Slocumb C., and Polley H. The effect of a hormone of the adrenal cortex (17-Hydroxy-11-Dehydrocorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meetings Mayo Clinic 24 (1949) 187-197
12. Yeager M., Guyre P., and Munck A. Glucocorticoid regulation of the inflammatory response to injury. Acta Anaesthesiol Scand 48 (2004) 799-813
13. Neeck G. Fifty years of experience with cortisone therapy in the study and treatment of rheumatoid arthritis. Ann NY Acad Sci 966 (2002) 28-38
14. Frei E., Karon M., Levin R., et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26 (1965) 642-656
15. Kriegler A., Bernardo D., and Verschoor S. Protection of murine bone marrow by dexamethasone during cytotoxic chemotherapy. Blood 83 (1994) 65-71
16. Macaya A., Munell F., Ferrer I., et al. Cell death and associated c-jun induction in perinatal hypoxia-ischemia: effect of the neuroprotective drug dexamethasone. Brain Res Mol Brain Res 56 (1998) 29-37
17. Pearl J., Nelson D., Schwartz S., et al. Glucocorticoids reduce ischemia-reperfusion-induced myocardial apoptosis in immature hearts. Ann Thorac Surg 74 (2002) 830-836
18. Zurita M., Vaquero J., Oya S., and Morales C. Effects of dexamethasone on apoptosis-related cell death after spinal cord injury. J Neurosurg 96 (2002) 83-89
19. Taylor S. Hormonal modification on the treatment of disseminated cancer of the breast. Am J Med 21 (1956) 688-696
20. Sui M., Chen F., and Fan W. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer (2005). published online Nov 8. DOI:10.1002/ijc.21743
21. Sherlock P., and Hartmann W. Adrenal steroids and the pattern of metastases of breast cancer. JAMA 181 (1962) 313-317
22. Iversen H., and Hjort G. The influence of corticoid steroids on the frequency of spleen metastases in patients with breast cancer. Acta Pathol Microbiol Scand 44 (1958) 205-212
23. Zhang C., Marme A., Wenger T., et al. Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int J Oncol 2 (2006) 551-558
24. Muenstedt K., Borces D., Bohlmann M., et al. Glucocorticoid administration in antiemetic therapy. Cancer 101 (2004) 1696-1702
25. Herr I., Ucur E., Herzer K., et al. Glucocorticoid co-treatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 63 (2003) 3112-3120
26. Postmus P., Smit E., Haaxma-Reiche H., et al., for the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Teniposide for brain metastases of small-cell lung cancer: a phase II study. J Clin Oncol 13 (1995) 660-665
27. Zhang C., Kolb A., Mattern J., et al. Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy. Cancer Letters (2005). published online Dec 9. DOI:10.1016/j.canlet.2005.10.037
28. Rasmuson T., Ljungberg B., Grankvist K., et al. Increased serum cortisol levels are associated with high tumour grade in patients with renal cell carcinoma. Acta Oncol 40 (2001) 83-87
29. Zhang C., Kolb A., Buchler P., et al. Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts, and established cell lines of pancreatic cancer. BMC Cancer 6 (2006) 61
30. Sorensen H., Mellemkjaer L., Nielsen G., et al. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 96 (2004) 709-711
31. Zhang C., Mattern J., Haferkamp A., et al. Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther 5 (2006) 59-64
32. Rieger J., Durka S., Streffer J., et al. Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. Eur J Pharmacol 365 (1999) 301-308
33. Gorman A., Hirt U., Orrenius S., and Ceccatelli S. Dexamethasone pre-treatment interferes with apoptotic death in glioma cells. Neuroscience 96 (2000) 417-425
34. Wolff J., and Jurgens H. Dexamethasone induced partial resistance to methotrexate in C6-glioma cells. Anticancer Res 14 (1994) 1585-1588
35. Benedetti S., Pirola B., Poliani P., et al. Dexamethasone inhibits the anti-tumor effect of interleukin 4 on rat experimental gliomas. Gene Ther 10 (2003) 188-192
36. Ekert P., MacLusky N., Luo X., et al. Dexamethasone prevents apoptosis in a neonatal rat model of hypoxic-ischemic encephalopathy (HIE) by a reactive oxygen species-independent mechanism. Brain Res 747 (1997) 9-17
37. Feng Z., Marti A., Jehn B., et al. Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. J Cell Biol 131 (1995) 1095-1103
38. Mikosz C., Brickley D., Sharkey M., et al. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk1. J Biol Chem 276 (2001) 16649-16654
39. Messmer U., Pereda-Fernandez C., Manderscheid M., and Pfeilschifter J. Dexamethasone inhibits TNF-alpha-induced apoptosis and IAP protein downregulation in MCF-7 cells. Br J Pharmacol 133 (2001) 467-476
40. Rutz H., Mariotta M., von Knebel Doeberitz M., and Mirimanoff R. Dexamethasone-induced radioresistance occurring independent of human papilloma virus gene expression in cervical carcinoma cells. Strahlenther Onkol 174 (1998) 71-74
41. Kamradt M., Mohideen N., Krueger E., et al. Inhibition of radiation-induced apoptosis by dexamethasone in cervical carcinoma cell lines depends upon increased HPV E6/E7. Br J Cancer 82 (2000) 1709-1716
42. Evans-Storms R., and Cidlowski J. Delineation of an antiapoptotic action of glucocorticoids in hepatoma cells: the role of nuclear factor-kappaB. Endocrinology 141 (2000) 1854-1862
43. Bailly-Maitre B., de Sousa G., Boulukos K., et al. Dexamethasone inhibits spontaneous apoptosis in primary cultures of human and rat hepatocytes via Bcl-2 and Bcl-xL induction. Cell Death Differ 8 (2001) 279-288
44. Gassler N., Zhang C., Schnabel P., et al. Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. Br J Cancer 92 (2005) 1084-1088
45. Bergman A., Pinedo H., and Peters G. Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells. Eur J Pharmacol 416 (2001) 19-24
46. Wen L., Madani K., Fahrni J., et al. Dexamethasone inhibits lung epithelial cell apoptosis induced by IFN-gamma and Fas. Am J Physiol 273 (1997) L921-L929
47. Sengupta S., Vonesch J., Waltzinger C., et al. Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J 19 (2000) 6051-6064
48. Kruit A., Reyes-Moreno C., Newling D., et al. Response of PC-3 prostate cancer cells to combination therapy using irradiation with glucocorticoids or doxorubicin. Anticancer Res 19 (1999) 3153-3156
49. Frankfurt O., and Rosen S. Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol 16 (2004) 553-563
50. Haid M. Steroid antiemesis may be harmful. N Engl J Med 304 (1981) 1237
51. Rutz H., and Herr I. Glucocorticoid administration in antiemetic therapy: is it safe?. Cancer 103 (2005) 2696
52. Fidler I., Gersten D., and Kripke M. Influence of immune status on the metastasis of three murine fibrosarcomas of different immunogenicities. Cancer Res 39 (1979) 3816-3821
53. Gorelick E., Segal S., and Feldman M. Control of lung metastasis progression in mice: role of growth kinetics of 3LL Lewis lung carcinoma and host immune reactivity. J Natl Cancer Inst 65 (1980) 1257-1264
54. Seshadri M., Poduval T., and Sundaram K. Studies on metastases. I. Role of sensitization and immunosuppression. J Natl Cancer Inst 63 (1979) 1205-1209
55. Birchmeier C., Birchmeier W., and Brand-Saberi B. Epithelial-mesenchymal transitions in cancer progression. Acta Anat (Basel) 156 (1996) 217-226
56. Uhr J., Scheuermann R., Street N., and Vitetta E. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 3 (1997) 505-509
57. Pantel K., and Woelfle U. Detection and molecular characterisation of disseminated tumour cells: implications for anti-cancer therapy. Biochim Biophys Acta 1756 (2005) 53-64
58. Poste G., and Fidler I. The pathogenesis of cancer metastasis. Nature 283 (1980) 139-146
59. Agosin M., Christen R., Badinez O., et al. Cortisone-induced metastases of adenocarcinoma in mice. Proc Soc Exp Biol Med 80 (1952) 128-131
60. Baserga R., and Shubik P. The action of cortisone on transplanted and induced tumors in mice. Cancer Res 14 (1954) 12-16
61. Iversen H.-G. The influence of cortisone on the frequency of tumour metastases. Acta Pathol Microbiol Scand 41 (1957) 273-280
62. Coman D. Mechanisms responsible for the origin and distribution of blood-borne tumor metastases: a review. Cancer Res 13 (1953) 397-404
63. Fischer F., and Hastrup B. Cortisone and calcium balance (effect of calcium, vitamin-D and methylandrostenediol). Acta endocrinol (Copenh) 16 (1954) 141-148
64. Coste F., and Bourel M. Experimental study of tissue permeability. C R Seances Soc Biol Fil 145 (1951) 1778-1781
65. Clawson B., and Nerenberg S. The effect of large doses of cortisone upon the ability of the reticuloendothelial cells to phagocytose streptococci. J Lab Clin Med 42 (1953) 746-748
66. Baserga R., and Shubik P. Action of cortisone on disseminated tumor cells after removal of the primary growth. Science 121 (1955) 100-101
67. Pomeroy T. Studies on the mechanism of cortisone induced metastases of transplanted mouse tumors. Cancer Res 14 (1954) 201-204
68. Boumpas D., Chrousos G., Wilder R., et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119 (1993) 1198-1208
69. von Knebel Doeberitz M., Koch S., Drzonek H., and Zur Hausen H. Glucocorticoid hormones reduce the expression of major histocompatibility class I antigens on human epithelial cells. Eur J Immunol 20 (1990) 35-40
70. Powell C., Mutch D., Kao M., et al. Dexamethasone used as an antiemetic in chemotherapy protocols inhibits natural cytotoxic (NC) cell activity. Cancer 65 (1990) 466-472
71. Collins J., Patek P., and Cohn M. Tumorigenicity and lysis by natural killers. J Exp Med 153 (1981) 89-106
72. Kao J., and Collins J. A rapid in vitro screening system for the identification and evaluation of anticancer drugs. Cancer Invest 7 (1989) 303-311